Merck’s targeted lung cancer drug tepotinib wins early access in UKThe UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small Share XMerck’s targeted lung cancer drug tepotinib wins early access in UKhttps://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/
FDA starts quick review of Merck’s MET-targeting lung cancer drugMerck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer Share XFDA starts quick review of Merck’s MET-targeting lung cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
